Opioid Side Effects, Post Operative Pain
Conditions
Keywords
nalbuphine dose
Brief summary
This study evaluate the adequate dose of mutonpain for laparoscopic cholecystectomy in the management of post operative pain. The investigators will randomize patients into three groups to compare the analgesia effects and side effects.
Detailed description
Nalbuphine is a FDA approved noncontrolled drug of opioid. And it had been applied for post operative pain for different surgeries, claiming that less nausea and vomiting with the same analgesic effect when comparing with morphine. However, several studies concerning post pain management usually used nalbuphine 0.15-0.3 mg/kg for laparoscopic cholecystectomy. If the analgesic effect of nalbuphine is similar with morphine, less nalbuphine injection could reduce the side effects of opioid. The investigators will randomize patients into three groups of different initial nalbuphine dose for post laparoscopic cholecystectomy surgical pain, and set patient control analgesia machine with nalbuphine for further pain management. If the pain or side effects of opioid were intolerable, the investigators will change pain medications into NSAIDs or other adequate medications to comfort the patient. The primary outcome were numerical rating pain score and consumption of nalbuphine. The secondary outcomes were nausea, vomiting, pruritus and satisfactory score, and if any other medications use.
Interventions
DRUGgroup A
mutonpain 0.05 mg/kg
DRUGgroup B
mutonpain 0.1 mg/kg
DRUGgroup C
mutonpain 0.2 mg/kg
Sponsors
Kaohsiung Medical University Chung-Ho Memorial Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* patient accept laparoscopic cholecystectomy * age:20-80 years old
Exclusion criteria
* nalbuphine allergy * chronic pain * active liver disease that would affect metabolization of nalbuphine * patient who had regular pain medications * patient who could not cooperate to the evaluation of the survey * dementia or other psychiatric disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Numerical Rating Pain Scale | numerical rating pain scale change at post-operative 1 hour, 2 hours, 4 hours, 24 hours, 36 hours | The Numerical Pain Rating Scale is a subjective measure in which individuals rate their pain on an eleven-point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain). The investors will measure the pain score at rest state and upon movement state at post-operative 1 hour, 2 hours, 4 hours, 24 hours, 36 hours. |
| consumption of nalbuphine | Record the opioid dose changes 2 days. | The investors will use patient control analgesia machine to calculate the time dependent dose of nalbuphine. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| use of rescue pain medications | record if any rescue pain medications at post operation 1 hour, 2 hours, 4 hours, 24 hours, 36 hours | if the patient use other pain medication on request of poor pain control or poor tolerant of the side effects of nalbuphine |
| vomiting | the vomiting episodes at post operation 1 hour, 2 hours, 4 hours, 24 hours, 36 hours | we will go to bed side and have an self-report episode of vomiting at 1 hour, 2 hours, 4 hours, 24 hours, 36 hours post operation |
| satisfactory score by net promoter score | 2 days | The net promoter score is a subjective measure in which individuals rate their satisfactory on an ten-point numerical scale. The scale is composed of 1 to 10. We will measure the net promoter score at the end of the study |
| nausea | the nausea sensation changes at post operation 1 hour, 2 hours, 4 hours, 24 hours, 36 hours | we will go to bed side and have an self-report episode of nausea at 1 hour, 2 hours, 4 hours, 24 hours, 36 hours post operation |
Other
| Measure | Time frame | Description |
|---|---|---|
| use of antipruritics | 2 days | if the patient use of antipruritics during the hospitalization |
| use of antiemetics | 2 days | if the patient use of antiemetics during the hospitalization |
Countries
Taiwan
Contacts
Primary ContactGuan-Yu Chen, MD
Backup ContactKuang-I Cheng, PhD
Outcome results
None listed